Depression Screening (18+)
GPRA/GPRAMA Measure

Indian Health Service
National GPRA Team
Depression-related GPRA measures

• Depression Screening 18+
  – Percentage of adults ages 18 and over who are screened for depression
  – GPRA measure since 2006
  – GPRAMA Measure since FY 2013

• Depression Screening age 12-17
  – Percentage of patients age 12-17 who are screened for depression.
  – New GPRA measure as of FY 2017
  – Other screening tools may be more appropriate for adolescents
Depression-related measures, cont.

• Antidepressant Medication Management: Acute Treatment
  – Percentage of patients with diagnosed depression who filled enough antidepressant medication prescriptions or refills to provide treatment for at least 84 days (12 weeks)

• Antidepressant Medication Management: Continuous Treatment
  – Percentage of patients with diagnosed depression who filled enough antidepressant medication prescriptions or refills to provide treatment for at least 180 days (6 months)
Depression Screening 18+

• Measures the proportion of eligible patients who have been screened for depression or diagnosed with a mood disorder during the report period.

• Eligible patients are all adults age 18 and older.
Measure Logic

**Denominator:**
Active Clinical patients ages 18 and older, broken down by gender.*

**Numerator:**
Patients screened for depression or diagnosed with a mood disorder at any time during the report period.

*CRS includes separate denominators for males and females, however the GPRA measure denominator includes both genders.
Federal and Tribal GPRA Results

**Depression Screening**
AI/AN patients ages 18 and older who have been screened for depression or diagnosed with a mood disorder within the past year.
Depression Statistics

• Each year, depression affects an estimated 9% of adults in the United States.

• Depression occurs 70% more frequently in women than in men.

• Depression increases the risk of suicidal behavior.

Depression and Type 2 Diabetes

• People with diabetes are almost twice as likely to develop depression as those who do not have a chronic medical condition.¹

• When combined with diabetes, depression contributes to poorer blood glucose control, more frequent hospital visits, higher risk of long-term complications, and a shorter life span.²


²Behavioral Diabetes Institute. (2011) Breaking Free From Depression and Diabetes: 10 Things You Need To Know And Do.
Recommendations for Depression Screening and Follow-up

Screen adult patients for depression when staff-assisted depression care supports are in place to assure accurate diagnosis, effective treatment, and follow-up.¹

If depression is diagnosed, intervention should include:

– collaborative care team
– patient-centered care
– focus on the patient’s chronic diseases
– routine monitoring using a standardized depression survey
– stepped treatment intensification
– follow-up¹,²


Recommended Screening Tools

**PHQ-9:**

- Scores each of the 9 DSM-IV criteria for depressive disorders
- Establishes diagnosis and grades symptom severity

Source: Pfizer Inc. (1999). Patient Health Questionnaire (PHQ-9). PRIME-MD
Importance of Depression Screening

• Without treatment, the frequency and severity of symptoms tend to increase over time

• Screening for depression is the first step to identifying patients who need help and follow-up

Documenting Depression Screening
18+ in CRS

• **Depression Screening**
  – Any of the following:
    • Exam code 36
    • POV ICD-9: V79.0
    • CPT 1220F, 3725F, G0444
    • BHS problem code 14.1 (screening for depression)
    • Measurement in PCC or BH of PHQ2, PHQ9 or PHQT

• **Mood Disorders**
  – At least two visits in PCC or BHS during the Report Period with POV for: Major Depressive Disorder, Dysthymic Disorder, Depressive Disorder NOS, Bipolar I or II Disorder, Cyclothymic Disorder, Bipolar Disorder NOS, Mood Disorder Due to a General Medical Condition, Substance-induced Mood Disorder, or Mood Disorder NOS. These POV codes are:
    • BHS POV 14, 15

• **Behavioral Health Clinic**
  – Clinic codes C4, C9, 14, 43, 48
IHS GPRA Measure Contacts

• Measure Lead:
  – Miranda Carman: miranda.carman@ihs.gov

• National GPRA Lead:
  – Diane Leach: diane.leach@ihs.gov

• National GPRA Support Team:
  – caogpra@ihs.gov